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OBJECTIVEdTo examine persistence of C-peptide production by ultrasensitive assay years
after onset of type 1 diabetes and factors associated with preserving b-cell function.
RESEARCH DESIGN AND METHODSdSerum C-peptide levels, a marker of insulin
production and surviving b-cells, were measured in human subjects (n = 182) by ultrasensitive
assay, as was b-cell functioning. Twenty-two times more sensitive than standard assays, this
assay’s lower detection limit is 1.5 pmol/L. Disease duration, age at onset, age, sex, and autoan-
tibody titers were analyzed by regression analysis to determine their relationship to C-peptide
production. Another group of four patients wasserially studied for up to 20 weeks to examine
C-peptide levels and functioning.
RESULTSdThe ultrasensitive assay detected C-peptide in 10% of individuals 31–40 years
afterdiseaseonsetandwithpercentageshigheratshorterduration.Levelsaslowas2.861.1pmol/L
responded to hyperglycemia with increased C-peptide production, indicating residual b-cell func-
tioning. Several other analyses showed that b-cells, whose C-peptide production was formerly
undetectable, were capable of functioning. Multivariate analysis found disease duration (b =
22.721; P = 0.005) and level of zinc transporter 8 autoantibodies (b = 0.127; P = 0.015)
signiﬁcantly associated with C-peptide production. Unexpectedly, onset at .40 years of age
was associated with low C-peptide production, despite short disease duration.
CONCLUSIONSdThe ultrasensitive assay revealed that C-peptide production persists for
decades after disease onset and remains functionally responsive. These ﬁndings suggest that
patients with advanced disease, whose b-cell function was thought to have long ceased, may
beneﬁt from interventions to preserve b-cell function or to prevent complications.
Diabetes Care 35:465–470, 2012
I
n type 1 diabetes, signiﬁcant destruc-
tion of b-cells occurs prior to diagno-
sis. At the time of clinical onset, only
;10% of normal b-cell mass remains (1).
Levels of plasma C-peptide drop to ;20%
ofthemaximalmeanofhealthypeople(2).
Aprospectivestudyfoundthat2yearsafter
diagnosis,insulinlevels,afteramixed-meal
stimulation, decreased to nearly 30% of
baseline (3). Similar ﬁndings contribute to
therapeutic nihilism that b-cells are nearly
destroyed several years after diagnosis, es-
pecially with early age of onset. But is this
pessimism warranted?
Studies show that patients with ad-
vanced disease do show some residual
b-cell function, depending on individual
variables(4–7).LoworvanishedC-peptide
levels are indicative of advancing disease
afterdiagnosis,andundetectableC-peptide
is usually observed after ;1 year of dis-
ease duration. Yet, even small amounts of
residual b-cell function confer fewer com-
plications in most studies (4,5,8,9,10).
The strongest evidence to date, however,
ﬁnds that while higher and sustained lev-
els of C-peptide are most beneﬁcial, even
modest levels of b-cell function in some
with long-term disease are associated
with lower rates of hypoglycemia and
lower incidence of retinopathy and ne-
phropathy (9,11).
Theﬁndingsraisequestionsabouthow
long insulin production persists, whether
b-cell functioning is fully maintained, and
what personal or disease factors predict re-
sidual b-cell function. Some studies indi-
cate the protective effectsofshorter disease
duration,higherageatonset,andfemale
sex, but not all studies agree (4,7,12–14).
IsletcellautoantibodiesGAD(GADA)and
islet antigen 2 (IA-2A) have been found
to be associated with rapid loss of b-cell
function (15),althoughother studies have
found them to be unrelated (2,16). The
recently discovered autoantibody zinc
transporter 8 (ZnT8A) has only begun to
be studied in relation to b-cell function
(17–19).
We studied 182 patients using an
ultrasensitive assay of C-peptide to assess
residual b-cell function. The assay is the
most sensitive available, with a detection
limitof1.5pmol/L.Weﬁrstcomparedthe
ultrasensitive with a commonly used
C-peptide assay, which had a detection
limitof33.1pmol/L,andthendetermined
whether b-cells above the lower detection
limit remained functional. Then, we ana-
lyzed the persistence of C-peptide persis-
tence over time, functional response to
hyperglycemia, and the relationship of
C-peptide with factors often associated
with residual b-cell function: disease du-
ration, chronological age, age at onset,
sex, and levels of autoantibodies GADA,
IA-2A, and ZnT8A (20). Having pro-
longed b-cell function enables patients,
once considered to lack C-peptide by
standard assay, to become candidates
for interventions to preserve or enhance
b-cell function or to prevent diabetes
complications.
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ORIGINAL ARTICLERESEARCH DESIGN AND
METHODSdPatients with type 1 di-
abeteswererecruitedovera10-yearperiod
by the Massachusetts General Hospital
withinformed consent.The studyreceived
full institutional approval. We studied
serum samples from 182 separate partic-
ipants for whom we had a complete set of
clinicalcharacteristics,listedinTable1,but
without any foreknowledge of C-peptide
values. When two or more samples were
available, the most recent sample was ana-
lyzed in order to include patients with the
most advanced disease. Serum had been
collectedandfrozenat2808Cuntilanalysis.
All blood samples tested for C-peptide as-
saywere,5yearsold.Noneofthepatients
whose samples were older than 5 years or
forwhomwedidnothavethecompleteset
of clinical characteristics, and who thus
could not be included, died or withdrew
from our clinical sample. Subjects were
askedtoappearintheresearchclinicfasting.
The most recent single serum sample was
collected and analyzed from each of the
182 subjects (Figs. 2 and 3 and Supple-
mentary Figs. 1 and 3).Their glycemiclev-
els were also evaluated. In addition to the
182 patients under study, we separately
evaluated four long-term patients, shown
in Fig. 1 and Supplementary Fig. 2, who
provided serum samples weekly for up
to 20 consecutive weeks. At one of the vis-
its, we tested each patient for fasting and
nonfasting–stimulated C-peptide. In some
oftheanalyses,wedidtestpatientsfornon-
fasting C-peptide levels (Supplementary
Fig. 2).
C-peptide samples for 182 subjects
were commercially tested by Mercodia
equipment (Uppsala, Sweden) using the
regular(cat.no.10-1136-01)orultrasen-
sitive (cat. no 10-1141-01) C-peptide
ELISA kits. Both assays were calibrated
against the International Reference Re-
agent for C-peptide, C-peptide 84/510 (a
World Health Organization standard),
and listed with the U.S. Food and Drug
Administration as Class I in vitro diagnos-
tic devices. Mercodia’s regular C-peptide
assay has a lower detection limit of 15
pmol/L with inter- and intra-assay coefﬁ-
cients of variation (CVs) at 4.8 and 4.8%,
respectively, at 304 pmol/L (cat. no. 10-
1136-01; Mercodia) (Supplementary
Table 1). The ultrasensitive assay’s lower
detection limit is 1.5 pmol/L, with inter-
and intra-assay CVs at 5.5 and 3.8% at 37
pmol/L (cat. no. 10-1141-01; Mercodia).
For the four serially followed subjects who
appearedintheclinicfasting,C-peptidelev-
els were ﬁrst tested at the Mayo Clinic,
which uses the standard C-peptide assay
(cat. no. 03184-897-190, Cobas; Roche
Diagnostics) (Fig. 1 and Supplementary
Table 1); then, these samples were restud-
ied inthe Mercodiaultrasensitive assay.The
Cobas assay’s range of detection is 330–
1470 pmol/L for the 5–95% range (Supple-
mentary Fig. 1) and can maintain a 1.9%
CV to 31 pmol/L. The percentages of CVs
are determined by SD/mean 3 100%.
For the rest of the samples in this study,
C-peptide levels were ﬁr s tt e s t e di nt h e
Mercodia ultrasensitive assay and, only if
sample valueswereabove therangeofthis
assay, then the few samples outside this
range were rerun in the Mercodia regular
assaythatthencapturedallsampleranges.
It should also be mentioned that all sam-
ples studied in either of the two Mercodia
assays were commercially run blinded by
the Mercodia laboratories, since their assay
performance data with automated plate
washes and other clinically standardized
innovations exceeded our abilities with
t h es a m et i g h tC V s .O n e - w a yA N O V A
was used to calculate intra- and interassay
variations. Autoantibodies GADA, IA–2A,
and ZnT8A were commercially measured
by Protein A radio binding assays at the
Diabetes Research Institute of Forscher-
gruppe Diabetes (Munich, Germany) as
previously described (17).
Statistical methods
UnpairedttestwithWelchcorrectionand
Pearson correlation test were used for all
182subjects.However,theunivariateand
multivariate regression analysis was lim-
itedto125patientsforwhomallvariables
were collected. We performed regression
analysis with Microsoft Excel and t tests
with Prism. P values #0.05 were consid-
ered signiﬁcant.
RESULTSdPatient characteristics of
182 type 1 diabetic subjects are listed in
Table1.C-peptidevaluesinserumsamples
from each patient were tested using the
Mercodia regular (Supplementary Fig. 1A)
and ultrasensitive C-peptide (Supplemen-
tary Fig. 1B) ELISA kits. Subjects’ median
age was 39 years (range 9–85), disease du-
ration 15 years (0–73), and age at onset 13
years (1–56). Levels of autoantibodies
GADA, IA-2A, and ZnT8A were obtained
for 125 of 182 subjects.
C-peptide levels and functional
capacity in serially studied patients
C-peptidelevelsforupto14weeklyserum
samples from four patients were ﬁrsttested
withstandard(Cobas)versusultrasensitive
(Mercodia) assay. The detection limits of
theseassaysarecomparedinSupplementary
Table 1dCharacteristics of study subjects
Characteristic
n 182
Male 55.5% (n =1 0 1 )
Race 100% Caucasian
HLA-A2 status 68% positive
HLA-DR status 26% DR1:4, 32% DR1:3, 25% DR3:4,
16% DR4:X, 1% miscellaneous
Age (years)
Median (range) 39 (9–85)
Mean 6 SD 37 6 17.4
Age at onset (years)
Median (range) 13 (1–56)
Mean 6 SD 17.8 6 13.5
Duration (years)
Median (range) 15 (0–73)
Mean 6 SD 19.4 6 15.7
Fasting C-peptide (pmol/L)
Median (range) 1.5 (1.5–1108)
Mean 6 SD 60.3 6 164
HbA1c (%)
Median (range) 7.1 (5.4–13)
Mean 6 SD 7.4 6 1.1
GADA 50.4
IA-2A 36.2
ZnT8A 28.3
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C-peptide and long-term diabetesTable 1. C-peptide levels in all serum sam-
ples tested by standard assay (n =5 4 )w e r e
belowitsdetectionlimitat33.1pmol/L(Fig.
1A), whereas C-peptide levels by ultrasensi-
tiveassaywereabovedetection(1.5pmol/L)
in 34 of 54 samples (63%) (Fig. 1B).
To determine whether the pancreas
retained functional activity in this group
of four patients, their blood samples,
assayed under fasting conditions and
stratiﬁed by glycemic level (normoglyce-
mia ,150 mg/dL vs. hyperglycemia
.150 mg/dL), were studied in relation
to C-peptide levels. In the ultrasensitive
butnotthestandardassay,samplesshow-
ing hyperglycemia (n = 12) were associ-
ated with higher C-peptide levels than
those showing normoglycemia (n = 50)
(Fig.1CandD).Similarﬁndingsoccurred
i nt h el a r g e rs a m p l eo f1 8 2p a t i e n t s ,a s
discussed below (Fig.3A–D).Thecharac-
teristics of the four patients, all of whom
are long-term patients with diabetes, are
listed in Supplementary Table 2.
Furthermore, glucose responsiveness
was examined in three patients with ad-
vanced serially followed up to20 weeks by
measurement of their C-peptide levels un-
der nonfasting conditions. The data show
thatatthreedifferentC-peptideranges,sub-
jectswithextremelylowC-peptide(Supple-
mentary Fig. 2, top panel), low C-peptide
(Supplementary Fig. 2, middle panel),
and moderate C-peptide (Supplementary
Fig. 2, bottom panel) levels all demon-
strated a linear relationship betweenglyce-
mic levels and C-peptide (Supplementary
Fig. 2). These ﬁndings suggest that b-cells
remain functional even in subjects with low
C-peptide output.
Disease duration and C-peptide levels
To test the relationship between C-peptide
and disease duration, additional diabetic
subjects(n=182)fromeachofwhomasin-
gle serum sample was obtained were cate-
gorized into these 5-year-duration groups:
0–5, 6–10, 11–20, 21–30, 31–40, and
.40 years (Fig. 2A). As disease duration
increased, C-peptide levels tended to grad-
ually decline, but this was a decline over
decades of diseasednot a decline over
months, as is commonly viewed to be the
course of the pancreas. The 0–5y e a r s
group exhibited higher C-peptide levels
than did the 6–10 years group (P =
0.0498). Similarly, the 6–10 years group
showed signiﬁcantly higher levels than
did the 31–40 years group (P = 0.0117).
In order of increasing duration, C-peptide
levelswereabovethedetectionlimitatrates
of 78.9, 59.5, 39.5, 39.1, 10, and 0% of
samples in the six groups (Fig. 2B).
Figure 2A shows that after 31–40
years of type 1 diabetes, two subjects ap-
peared to produce detectable C-peptide.
Individual characteristics of these subjects
wereexaminedtodeterminewhetherthere
was anything unusual about their clinical
course. The ﬁrst subject was a male who
had classic onset of type 1 diabetes in
childhood, remained thin all his life,
demonstrated a history of ketones early
in life, and had a positive family history
ofbothtype1diabetes(siblings)andother
autoimmune diseases. As expected from
thesustainedC-peptidelevels,thissubject
had excellent HbA1C values and no com-
plications. Patient Balso had classic type 1
diabetes,withonsetat10yearsofage;was
thin; and had hypothyroidism and a very
positivefamilyhistoryofautoimmunedis-
eases. He was still positive for both GADA
and IA-2A after 35 years of disease and
also had no complications. These two pa-
tients are dramatic examples to support
past population-based studies that any
preservation of C-peptide is associated
with decreased complications (10).
Functional capacity of b-cells in a
large clinical sample
In addition to the two previous analyses
of functionality in smaller samples, we
sought to use the ultrasensitive assay to
determinefunctionalcapacityofb-cellsin
Figure 1dSensitivity of standard (Cobas/Roche) versus ultrasensitive (Mercodia) C-peptide
assays in a cohort of individuals with type 1 diabetes for whom weekly samples were taken for up
to 20 weeks (n = 4 subjects, n = 54 blood samples). Each blood sample was tested by both assays.
The shaded areas represent the areas below the detection limits of the assay. A: Standard assay
failed to detect C-peptide in any of the selected serum sample. The shaded area across the lower
portionofthepaneldisplaysthelimitofdetectionoftheCobasassay(33.1pmol/L),alimitdeﬁned
asamaintainedCVof1.9%.B:UltrasensitiveassaydetectedC-peptideinthemajorityofthesame
samples. The dashed horizontal line acrossthe entire lower portion of the panel displays the limit
of detection (1.5 pmol/L). C and D: Samples taken from four patients studied for functional re-
sponses to glycemic level. Samples depicting hyperglycemia (glucose .150 mg/dL) and nor-
moglycemia (glucose #150 mg/dL) revealed that C-peptide level was elevated with mild
hyperglycemia, as opposed to normoglycemia, by ultrasensitive assay (D). The standard assay is
notsensitiveenoughtorevealthisfunctionalresponse(C).(Ahigh-qualitycolorrepresentationof
this ﬁgure is available in the online issue.)
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Wang, Lovejoy, and Faustmanan analysis of our large clinical sample by
stratifying patients with and without hy-
perglycemia. Glycemic levels were di-
vided into hyperglycemic (n =5 2 )a n d
normoglycemic (n = 52) groups and
then compared, with C-peptide levels
grouped into four ranges: 0–1.5 pmol/L
(nonresponsive), 1.5–5 pmol/L (respon-
sive), 5–100 pmol/L, and .100 pmol/L
(responsive). Samples from hyperglyce-
mic subjects had signiﬁcantly higher
C-peptide levels than did those from
normoglycemic subjects in each of the
C-peptide level ranges, except for the non-
responsive group, which had C-peptide
levels below the level of detection of the
ultrasensitive assay. As long as C-peptide
levels were within the detection range of
the ultrasensitive assay, C-peptide levels
were responsive to glycemic levels.
Age at onset
C-peptide levelswerestudied byage at on-
set, which was categorized into six groups:
0–5y e a r s( N = 28), 6–10 years (N =3 7 ) ,
11–20years(N=57),21–30years(N=25),
31–40 years (N =1 9 ) ,a n d.40 years
(N = 16) (Fig. 3E and F). C-peptide levels
with onset at 31–40 years of age (mean 6
SD 210 6 342 pmol/L) were signiﬁcantly
higherthanthose with onset at 0–5years
of age (11 6 34). This is generally consis-
tentwithabelievedslowerdiseaseonsetin
olderpatients.Patientswithonsetat31–40
years of age had the highest C-peptide
levels (210 6342.75 pmol/L). The excep-
tion to these data and generally accepted
concept was that the next age-of-onset
group, .40 years, had lower C-peptide
levels, 63 6 90.23 pmol/L, despite short
diseaseduration(Fig.3EandF).Allgroups
tended to exhibit shorter disease dura-
tion as age at onset increased (Fig. 3F).
The 31–40 years group produced the
highest C-peptide levels, with duration
signiﬁcantly shorter than in the younger
groups. Therefore, our data show that
C-peptide can be present for decades after
disease onset, suggesting that long-term
preservation of pancreatic function and
C-peptide production is not conﬁned to a
shorttime(;1year)afterclinicalonsetbut,
rather, persists in some cases beyond 30
years (Fig. 3F). A possible exception to
this rule that needs to be conﬁrmed in
further studies, and in additional subject
sets,iswhethernew-onsettype1diabetes
in subjects older than 40 years of age
mightbeassociatedwithacceleratedpan-
creas loss.
Autoantibodies and sex
GADA was found in the highest fraction
of patients (50.4%) (Table 1) but was un-
related in a linear regression analysis of
factors affecting C-peptide production ei-
ther as a univariate or multivariate analy-
sis (Supplementary Table 2). IA-2A and
ZnT8A autoantibodies were positively
correlated with C-peptide levels (Supple-
mentary Table 2). GADA, IA-2A, and
ZnT8A were combined and treated as
fourseparategroupsof3,2,1,or0positive
autoantibodies. No substantial differences
were found among the number of positive
autoantibodies and C-peptide levels (Sup-
plementary Fig. 3B). Sex was unrelated to
C-peptide levels (Supplementary Table 2
and Supplementary Fig. 3A).
Multivariate analysis
By univariate regression analysis, duration,
chronological age, IA-2A, and ZnT8A were
signiﬁcantly correlated with C-peptide lev-
els,whileageatonset,sex,andGADAwere
not (Supplementary Table 2). Considering
Figure 2dThe relationships betweenC-peptide production and disease duration in subjects with
type 1diabetes(n=182)byultrasensitiveassay.A:Stratiﬁed by sixintervalsof disease duration,
inyears,subjectswithshorterdiseasedurationtendedtoproducehigherlevelsofC-peptidebythe
ultrasensitive assay for values up to 230 pmol/L or with the Mercodia regular assay for values
.230 pmol/L, which persisted decades after disease onset. The shaded area across the lower
portion of the panel displays the limit of detection of the ultrasensitive assay 1.5 pmol/L.
B: Percentage of patients with detectable C-peptide above detection limits. (A high-quality color
representation of this ﬁgure is available in the online issue.)
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C-peptide and long-term diabetesthe close correlation between duration and
chronologicalage(r=0.6757,P,0.0001)
(Supplementary Fig. 3C), all factors ex-
ceptagewerechosenasindependentvar-
iables for multivariate analysis. Duration
and ZnT8A emerged as the only factors
signiﬁcantly related to C-peptide levels
in multivariate analysis (Supplementary
Table 2).
CONCLUSIONSdInsummary, results
revealed that 1)t h eu l t r a s e n s i t i v ea s s a y ,
which dramatically improved detection at
low C-peptide ranges, found that 10% of
patients with disease duration of three to
four decades still produced C-peptide; 2)
b-cell functioning was intact at C-peptide
levels as low as 2.8 6 1.1 pmol/L; 3)s t i l l ,
longer disease duration was associated
with lower levels of C-peptide, according
to multivariate analysis; and 4) although
some studies have shown that adult-onset
diabetes confers a more benign course,
subjects in this study with onset at .40
years of age showed a more rapid loss of
C-peptide levels despite relatively short
disease duration.
With standard assays, many patients
are assessed as having lost considerable
insulin secretion by the time type 1 di-
abetesisdiagnosed(2,3).Yetevenlowlev-
els of insulin or C-peptide are consistently
linked to lower frequency of late-stage
complications (10). Using an ultrasen-
sitive assay, this study found C-peptide
detection and functional capacity at
levels heretofore thought to be indica-
tiveofb-celldestruction.Theﬁndingsap-
pear to dispute therapeutic nihilism that
b-cell functioning cannot be preserved
long after diagnosis and suggest a long
course of pancreas activity postdiagnosis
(Fig. 3G). They also appear to dispute the
viewthatonsetinadulthoodislessaggres-
sive than in childhood. While onset at
31–40 years of age is generally more be-
nign,thesepreliminarydatasuggestthatit
might be possible that diabetes onset after
age 40 years is associated with dramati-
cally lower C-peptide levels, despite short
duration. One reason may be that basal
C-peptide production is lower in healthy
olderadults thaninyoungerones(21,22).
Related reasons may be that older adults
have less b-cell proliferative and regenera-
tive capacity, shifts in epitopes, and higher
levels of proinﬂammatory cytokines and
metabolic control (22). Further studies in
the future are needed to conﬁrm these ob-
servations in additional subsets of long-
termpatientswithdiabetesandtocompare
various assays (23). In this study, we saw
moresubjects withC-peptideovera40year
periodbutfew subjects with C-peptideafter
40 years.
Our ﬁnding of a strong relationship
between longer duration and lower
C-peptide is consistent with the ﬁndings
of previous studies (13). The ﬁnding of a
strong relationship between higher levels
of ZnT8A autoantibodies and higher
levels of C-peptide is difﬁcult to inter-
pret. Autoantibodies are generally good
predictors for disease onset but are not
speciﬁc regarding disease outcome
(18,20). The recently discovered ZnT8A
autoantibody is reported to decline with
disease duration, especially 25 years’ dura-
tion, but the reasons behind this relation-
ship are highly complex (19). Greater
investigation of ZnT8A is clearly needed.
Figure 3dInvestigating functionality of insulin-secreting b-cells based on blood glucose (A–D)o r
age at onset and lifetime duration of the C-peptide response (E and F)d e ﬁnes the time line of per-
sistent C-peptide section (G). Hyperglycemic (n =5 2 )o rn o r m o g l y c e m i c( n = 52) samples were
examined in the same subjects (n = 52), who gave samples on consecutive weeks and stratiﬁed into
fourrangesofC-peptidelevels:0–5pmol/L(nonresponsive),0–5pmol/L(responsive),5–100pmol/L,
and .100 pmol/L (A–D). Signiﬁcantly higher C-peptide levels were produced in hyperglycemic
samples, except around the lower levels of assay detection (range 0–5 pmol/L), where b-cells from
some samples did not respond to hyperglycemia. Subjects divided into six groups based on age at
onset produced varying levels of C-peptide, with the highest levels produced at ages 31–40 years
andasuddendropinthegroup.40yearsoldandstudiedforremainingC-peptidesecretion(Eand
F). C-peptide production during and after type 1 diabetes diagnosis. Reduction of C-peptide levels
startssometimeduringtheprediabetesstageandkeepsgoingdownwiththeprogressofthedisease.
WiththenewultrasensitiveC-peptideassays,remainingb-cellfunctionextendsforyearsafterloss
of pancreas function and in some cases extends to 40 years after diagnosis (G).
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Wang, Lovejoy, and FaustmanIn conclusion, decades after onset,
C-peptide detection and functioning
b-cells are observed with an ultrasensitive
assay.Theassayoffersanovelapproach to
identify patients, even with advanced dis-
ease,whouponglycemicstimulationmay
beneﬁt from treatments to retain or en-
hance b-cell function. Patients with low
C-peptidelevelsoradvanceddisease should
neither be uniformly excluded from clin-
ical trials nor seen as having complete is-
let cell destruction.
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